TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has announced that its Recombinant anti-human IL-17A/F Humanized Monoclonal Antibody Injection, developed in collaboration with Beijing Kanova Biopharmaceutical, has achieved the primary endpoint in a phase III clinical trial for moderate-to-severe plaque psoriasis. The trial results demonstrated that the drug, LZM012, is non-inferior and even superior to the control drug secukinumab, with a faster onset of action and sustained benefits over time. The company is advancing towards market launch by submitting an application to the National Medical Products Administration, which could enhance its positioning in the psoriasis treatment market.
The most recent analyst rating on (HK:1513) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group is a company involved in the pharmaceutical industry, focusing on the development and production of therapeutic biological products. Its primary products include humanized monoclonal antibody injections, with a market focus on innovative treatments for conditions like psoriasis.
YTD Price Performance: 42.04%
Average Trading Volume: 1,889,324
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.75B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.